Name (Synonyms) | Correlation | |
---|---|---|
drug1447 | Unfractionated heparin SC Wiki | 1.00 |
drug1445 | Unfractionated Heparin IV Wiki | 1.00 |
drug474 | Enoxaparin 40 Mg/0.4 mL Injectable Solution Wiki | 1.00 |
drug331 | Clopidogrel Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D054556 | Venous Thromboembolism NIH | 0.45 |
D013923 | Thromboembolism NIH | 0.33 |
D013927 | Thrombosis NIH | 0.28 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.
Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia, or clinically silent DVT
Measure: Primary endpoint: Venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlierDescription: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia
Measure: Key secondary endpoint: Clinically evident venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlier